3-(3-pyridinyl)-3,9-diazabicyclo[4.2.1]nonane | 286945-74-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-(3-pyridinyl)-3,9-diazabicyclo[4.2.1]nonane
• 英文别名: 3-pyridin-3-yl-3,9-diaza-bicyclo[4.2.1]nonane；3-(Pyridin-3-yl)-3,9-diazabicyclo[4.2.1]nonane；3-pyridin-3-yl-3,9-diazabicyclo[4.2.1]nonane
• CAS: 286945-74-2
• 化学式: C₁₂H₁₇N₃
• 分子量: 203.287
• InChiKey: IMAFPMMJFGWHQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(3-pyridinyl)-3,9-diazabicyclo[4.2.1]nonane 、 对甲苯磺酸 生成 3-(3-pyridinyl)-3,9-diazabicyclo[4.2.1]nonane bis(4-methylbenzenesulfonate)
  参考文献：
  名称：

  DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS

  摘要：

  公开号：

  EP1147112B1

文献信息

• Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
  申请人：Link T. James

  公开号：US20050277647A1

  公开（公告）日：2005-12-15

  The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

  本发明涉及抑制11-β-羟基类固醇脱氢酶1型酶的化合物。本发明还涉及利用11-β-羟基类固醇脱氢酶1型酶的抑制剂治疗非胰岛素依赖型2型糖尿病、胰岛素抵抗、肥胖、脂质紊乱、代谢综合征以及其他由过度糖皮质激素作用介导的疾病和症状。
• Diazabicyclic CNS active agents
  申请人：——

  公开号：US20030225268A1

  公开（公告）日：2003-12-04

  Compounds of formula I: 1 or pharmaceutically acceptable salts thereof, are useful for controlling synaptic transmission in mammals.

  公式I：1的化合物或其药用盐对于控制哺乳动物的突触传递是有用的。
• INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME
  申请人：Pliushchev Marina A.

  公开号：US20100222316A1

  公开（公告）日：2010-09-02

  The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

  本发明涉及一种抑制11-beta-羟基类固醇脱氢酶1型酶的化合物。本发明还涉及使用11-beta-羟基类固醇脱氢酶1型酶的抑制剂治疗非胰岛素依赖性2型糖尿病、胰岛素抵抗、肥胖症、脂质代谢紊乱、代谢综合征和其他由过度糖皮质激素作用介导的疾病和病况。
• METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME
  申请人：AbbVie Inc.

  公开号：US20130338169A1

  公开（公告）日：2013-12-19

  The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

  本发明涉及11-β-羟基类固醇脱氢酶1型酶抑制剂及其在治疗非胰岛素依赖性2型糖尿病、胰岛素抵抗、肥胖症、脂质代谢紊乱、代谢综合征、中枢神经系统疾病以及与过度糖皮质激素相关的疾病和病症中的应用。
• Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
  申请人：ABBOTT LABORATORIES

  公开号：EP1359152A2

  公开（公告）日：2003-11-05

  Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein: V is selected from the group consisting of a covalent bond and CH2; W is selected from the group consisting of a covalent bond, CH2 and CH2CH2; X is selected from the group consisting of a covalent bond and CH2; Y is selected from the group consisting of a covalent bond, CH2 and CH2CH2; Z is selected from the group consisting of CH2 and CH2CH2, and CH2CH2CH2; L1 is selected from the group consisting of a covalent bond and (CH2)n; n is 1-5; R1 is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), and (l); R2 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, aminoalkyl, aminocarbonylalkyl, benzyloxycarbonyl, cyanoalkyl, dihydro-3-pyridinylcarbonyl, hydroxy, hydroxyalkyl, phenoxycarbonyl, and -NH2; are useful for controlling synaptic transmission in mammal.

  式(I)化合物或其药学上可接受的盐 其中 V 选自由共价键和 CH2 组成的组； W 选自由共价键、CH2 和 CH2CH2 组成的组； X 选自由共价键和 CH2 组成的组； Y 选自由共价键、CH2 和 CH2CH2 组成的组； Z 选自 CH2 和 CH2CH2 及 CH2CH2CH2 组成的组； L1 选自由共价键和 (CH2)n 组成的组； n 为 1-5； R1 选自由(a)、(b)、(c)、(d)、(e)、(f)、(g)、(h)、(i)、(j)、(k)和(l)组成的组； R2 选自氢、烷氧羰基、烷基、氨基烷基、氨基羰基烷基、苄氧羰基、氰基烷基、二氢-3-吡啶基羰基、羟基、羟基烷基、苯氧羰基和-NH2 所组成的组； 可用于控制哺乳动物的突触传递。